Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Dragonfly Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DF-1001,Pembrolizumab

            Therapeutic Area: Oncology Product Name: DF-1001

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $12.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 10, 2020

            Details:

            Bristol-Myers Squibb has licensed its fourth TriNKET™ immunotherapy drug candidate from Dragonfly.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interleukin 12,Pembrolizumab

            Therapeutic Area: Oncology Product Name: DF6002

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2020

            Details:

            DF6002. Dragonfly's DF6002 clinical trial is currently recruiting patients with advanced solid tumors at Lifespan Cancer Institute at Rhode Island Hospital, the principal teaching hospital of Brown University, with additional sites scheduled to open shortly.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NK cell Engager Therapies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Undisclosed Upfront Cash: $55.0 million

            Deal Type: Licensing Agreement July 06, 2020

            Details:

            Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.